孟濤 李玉霞 李衛(wèi)華 潘華剛 張淞 王曉
[摘要]?目的?研究上調(diào)基因11(URG11)對骨肉瘤細胞(MG63)惡性表型的影響。
方法?用URG11短發(fā)夾RNA(shRNA)重組慢病毒感染細胞,以實時熒光定量PCR(qRT-PCR)和蛋白免疫印跡(Western blot)檢測干擾效果。四甲基偶氮唑鹽比色法(MTT)測定細胞增殖,流式細胞術(shù)測定細胞凋亡,Transwell檢測細胞侵襲和遷移,Western blot檢測裂解的半胱氨酸蛋白酶-9(Cleaved Caspase-9)、基質(zhì)金屬蛋白酶2(MMP-2)、E-鈣黏蛋白(E-cadherin)、裂解的半胱氨酸蛋白酶-3(Cleaved Caspase-3)、基質(zhì)金屬蛋白酶9(MMP-9)和波形蛋白(Vimentin)等表達。
結(jié)果?URG11 shRNA重組慢病毒感染MG63細胞后,URG11表達下降,差異有顯著性(F=181.200、97.307,P<0.001);細胞存活率、侵襲和遷移數(shù)量降低,細胞凋亡率升高,E-cadherin、Cleaved Caspase-9、Cleaved Caspase-3蛋白表達水平升高,Vimentin、MMP-9和MMP-2蛋白表達水平降低,差異均有顯著性(F=28.064~625.516,P<0.05)。
結(jié)論?shRNA干擾URG11表達可抑制骨肉瘤細胞增殖、侵襲、遷移和上皮間質(zhì)轉(zhuǎn)化,并誘導細胞凋亡。
[關(guān)鍵詞]?骨肉瘤;上調(diào)基因11;腫瘤侵潤;細胞運動;細胞凋亡
[中圖分類號]?R738.1
[文獻標志碼]?A
[文章編號]??2096-5532(2019)06-0634-05
doi:10.11712/jms201906002
[開放科學(資源服務)標識碼(OSID)]
EFFECT OF SHRNA INTERFERENCE WITH EXPRESSION OF URG11 ON MALIGNANT PHENOTYPE OF OSTEOSARCOMA CELLS
MENG Tao, LI Yuxia, LI Weihua, PAN Huagang, ZHANG Song, WANG Xiao
(Department of Orthopaedics, Huaihe Hospital, He′nan University, Kaifeng 475001, China)
[ABSTRACT] Objective To study the effect of up-regulated gene 11 (URG11) on the malignant phenotype of osteosarcoma cells (MG63).
Methods The cells were infected with URG11 short hairpin RNA (shRNA) recombinant lentivirus, and the interference effect was determined by real-time quantitative PCR (qRT-PCR) and Western blot. Cell proliferation was determined by MTT assay, cell apoptosis was determined by flow cytometry, and cell invasion and migration were determined by Transwell assay. Western blot was used to determine the expression of cleaved caspase-9, matrix metalloproteinase 2 (MMP-2), E-cadherin, cleaved caspase-3, matrix metalloproteinase 9 (MMP-9), and Vimentin.
Results After MG63 cell infection with URG11 shRNA recombinant lentivirus, URG11 expression was significantly reduced (F=181.200 and 97.307,P<0.001). There were significant decreases in cell survival rate, number of cells with invasion and migration, and expression levels of Vimentin, MMP-9, and MMP-2 proteins, but there were significant increases in cell apoptosis rate and expression levels of E-cadherin, cleaved caspase-9, and cleaved caspase-3 proteins (F=28.064-625.516,P<0.05).
Conclusion shRNA interference with URG11 expression can inhibit the proliferation, invasion, migration, and epithelial-mesenchymal transition of osteosarcoma cells and induce cell apoptosis.
[KEY WORDS] osteosarcoma; up-regulated gene 11; neoplasm invasiveness; cell movement; apoptosis
骨肉瘤是一種好發(fā)于青壯年和青少年的惡性骨腫瘤[1],其惡性表型如增殖、凋亡、侵襲等與細胞內(nèi)異常表達基因有關(guān)[2]。上調(diào)基因11(URG11)是近年來發(fā)現(xiàn)的參與細胞運動、增殖等過程的基因[3],且在胃癌、肝癌等中發(fā)揮癌基因作用,下調(diào)URG11腫瘤生長和轉(zhuǎn)移能力減弱[4-5]。URG11在骨肉瘤組織中呈陽性表達,且與腫瘤病人分期、轉(zhuǎn)移相關(guān),但其在骨肉瘤細胞中的作用尚不明確[6]。本實驗通過干擾URG11的表達,探討URG11對骨肉瘤細胞惡性表型的影響,為靶向URG11治療骨肉瘤提供依據(jù)。
1?材料與方法
1.1?細胞和試劑
骨肉瘤細胞MG63購自上海研謹生物科技有限公司;polybrene購自美國Sigma公司;SYBR定量PCR試劑盒購自天根生化科技(北京)有限公司;陰性對照慢病毒和URG11短發(fā)夾RNA(shRNA)重組慢病毒由吉滿生物科技(上海)有限公司構(gòu)建;基質(zhì)金屬蛋白酶2(MMP-2)抗體、URG11抗體購自美國Abcam;裂解的半胱氨酸蛋白酶-3(Cleaved Caspase-3)抗體、基質(zhì)金屬蛋白酶9(MMP-9)抗體、E-鈣黏蛋白(E-cadherin)抗體、
裂解的半胱氨酸蛋白酶-9(Cleaved Caspase-9)抗體、波形蛋白(Vimentin)抗體購自美國Santa Cruz Biotechnology。
1.2?慢病毒感染
骨肉瘤細胞以每孔5×104個接種6孔板,于培養(yǎng)箱內(nèi)培養(yǎng),細胞融合度為40%時,以MOI=20分別添加慢病毒,再加入適量的polybrene(終濃度為5 mg/L);培養(yǎng)12 h以后,加入新鮮培養(yǎng)液;培養(yǎng)72 h后熒光顯微鏡下觀察熒光表達情況,以1 mg/L的嘌呤霉素篩選穩(wěn)定轉(zhuǎn)染的細胞系。把不感染慢病毒的細胞設(shè)置為Control組(A組),把感染陰性對照慢病毒以及URG11 shRNA重組慢病毒的細胞分別設(shè)置為shRNA-NC(B組)、URG11 shRNA(C組)。
1.3?實時熒光定量PCR(qRT-PCR)測定干擾效果
A、B、C組細胞提取總RNA,反轉(zhuǎn)錄成cDNA后進行qRT-PCR。所用引物種類及其序列見表1。用SYBR定量PCR試劑盒分析URG11表達變化,計算方法為2-△△CT法,內(nèi)參為β-actin。每組實驗重復3次,每次設(shè)3個復孔。
1.4?蛋白免疫印跡(Western blot)測定干擾效果
A、B、C組細胞分別用PBS洗滌2次,再加入含有PMSF的RIPA裂解溶液,于冰上孵育30 min。以BCA法測定蛋白樣品濃度,每孔30 μg蛋白樣品,設(shè)置120 V的電壓電泳2 h后,從玻璃板中間取出凝膠。將PVDF膜置于甲醇中孵育10 s以后進行轉(zhuǎn)膜,轉(zhuǎn)膜置于4 ℃條件進行。將PVDF膜置于新配置的含體積分數(shù)0.05牛血清蛋白溶液中,在室溫結(jié)合2 h。把URG11一抗按1∶800倍稀釋,PVDF膜置于一抗反應液中孵育過夜。再將二抗按1∶2 000倍稀釋后,把PVDF膜置于二抗反應液內(nèi)孵育2 h。使用ECL發(fā)光。采用Image J分析內(nèi)參β-actin和目的條帶URG11的灰度值,URG11蛋白水平=URG11的灰度值/β-actin的灰度值。每組實驗重復3次,每次設(shè)3個復孔。
1.5?四甲基偶氮唑鹽比色法(MTT)檢測細胞增殖
A、B、C組細胞培養(yǎng)24 h,添加20 μL的MTT溶液和180 μL細胞培養(yǎng)液至每個孔內(nèi)培養(yǎng)4 h,再加入150 μL的二甲基亞砜,混合反應后,經(jīng)空白孔調(diào)零。以酶標儀檢測570 nm波長處的吸光度(A)值,把Control細胞的存活率設(shè)置為100%,分析其他各組細胞存活率變化。每組實驗重復3次,每次設(shè)3個復孔。
1.6?流式細胞術(shù)檢測細胞凋亡
A、B、C組細胞中分別添加500 μL的Binding Buffer,混合后再添加PI和Annexin V-FITC染液孵育15 min,置于流式細胞儀中檢測細胞凋亡變化。每組實驗重復3次,每次設(shè)3個復孔。
1.7?Transwell小室檢測細胞侵襲和遷移
A、B、C組細胞以不含血清的培養(yǎng)液懸浮,細胞密度調(diào)整為7×107/L,分別添加到Transwell小室的上室內(nèi)進行遷移實驗。每組添加200 μL細胞懸液,下室內(nèi)添加500 μL的含血清培養(yǎng)液。24 h后,將小室取出,把沒有穿膜的細胞擦掉并以PBS洗滌后,分別添加多聚甲醛溶液固定30 min,添加甲紫染色后,在光鏡下選取5個視野,計數(shù)細胞遷移數(shù)目。在侵襲實驗前以基質(zhì)膠將Transwell小室濕化,其余步驟同遷移實驗。每組實驗重復3次,每次設(shè)3個復孔。
1.8?Western blot檢測細胞中相關(guān)蛋白表達變化
A、B、C組細胞按照1.4中Western blot方法檢測Cleaved Caspase-3、MMP-9、Cleaved Caspase-9、E-cadherin、MMP-2和Vimentin蛋白表達變化。每組實驗重復3次,每次設(shè)3個復孔。
1.9?統(tǒng)計分析
采用SPSS 21.0軟件分析實驗數(shù)據(jù),計量資料數(shù)據(jù)用±s表示,多組差異比較用單因素方差分析,組間比較用SNK-q檢驗,以P<0.05為差異有統(tǒng)計學意義。
2?結(jié)?果
2.1?URG11 shRNA下調(diào)對骨肉瘤細胞中URG11表達水平影響
URG11 shRNA慢病毒感染后骨肉瘤細胞中URG11 mRNA和蛋白表達水平明顯下降,差異有顯著性(F=181.200、97.307,P<0.001)。URG11 shRNA可下調(diào)骨肉瘤細胞中URG11表達和轉(zhuǎn)錄。見圖1和表2。
2.2?URG11 shRNA對骨肉瘤細胞增殖和凋亡的影響
URG11 shRNA慢病毒感染后骨肉瘤細胞存活率降低、凋亡率升高,差異有顯著意義(F=28.897、625.516,P<0.05)。下調(diào)URG11可抑制骨肉瘤細胞增殖并誘導細胞凋亡。見圖2和表3。
2.3?URG11 shRNA對骨肉瘤細胞侵襲和遷移影響
URG11 shRNA慢病毒感染后骨肉瘤細胞侵襲和遷移數(shù)目降低,差異有統(tǒng)計學意義(F=93.373、101.207,P<0.001)。下調(diào)URG11可抑制骨肉瘤細胞侵襲和遷移。見表4。
2.4?URG11 shRNA對骨肉瘤細胞中相關(guān)蛋白表達影響
URG11 shRNA慢病毒感染后,骨肉瘤細胞中凋亡蛋白Cleaved Caspase-3、Cleaved Caspase-9表達水平升高,侵襲和遷移蛋白MMP-2、MMP-9表達水平降低,間質(zhì)細胞標志物Vimentin蛋白表達水平下降,上皮細胞標志物E-cadherin蛋白表達水平升高,差異均具有統(tǒng)計學意義(F=28.064~148.737,P<0.01)。下調(diào)URG11則能夠抑制骨肉瘤細胞中MMP-2、MMP-9蛋白表達,促進Cleaved Caspase-3、Cleaved Caspase-9蛋白表達,并且對細胞上皮間質(zhì)轉(zhuǎn)化(EMT)具有抑制作用。見圖3和表5。
3?討?論
URG11是被HBx蛋白上調(diào)的基因,與腫瘤的發(fā)生、發(fā)展和轉(zhuǎn)移密切相關(guān)[7-8]。有報道顯示,在胃癌、前列腺癌、胰腺癌、肝癌等腫瘤中URG11高表達,下調(diào)URG11表達后腫瘤細胞生長、侵襲能力減弱,說明URG11可能在腫瘤中充當癌基因[4,9-11]。
研究顯示,URG11高表達于骨肉瘤組織,且與骨肉瘤病人存活時間、轉(zhuǎn)移等有關(guān)[6]。本文結(jié)果表明,下調(diào)URG11后的骨肉瘤細胞的增殖能力和侵襲遷移能力降低,細胞凋亡率升高,說明下調(diào)URG11可以抑制骨肉瘤細胞的惡性表型,其作用與之前在其他腫瘤中研究報道一致。
細胞凋亡受多種因素共同調(diào)控,其中Caspase蛋白家族是目前研究較為透徹的凋亡蛋白[12]。位于Caspase凋亡反應上游的蛋白成員如Caspase-9激活后可以促進凋亡反應的發(fā)生,而位于凋亡反應下游的Caspase-3激活后誘導細胞凋亡[13-14]。而且二者只有被激活后形成Cleaved Caspase-3、Cleaved Caspase-9才可發(fā)揮促細胞凋亡功能[15-16]。文獻報道,蟲草素可通過上調(diào)Cleaved Caspase-3、Cleaved Caspase-9蛋白的表達誘導細胞凋亡,從而發(fā)揮抗骨肉瘤的作用[17];雷公藤紅素也提高了骨肉瘤細胞HOS中Cleaved Caspase-3、Cleaved Caspase-9的表達而使細胞凋亡[18]。本文結(jié)果顯示,下調(diào)URG11表達后的骨肉瘤細胞中Cleaved Caspase-3、Cleaved Caspase-9蛋白表達水平升高,這說明下調(diào)URG11可能激活Caspase凋亡反應,這與細胞凋亡檢測結(jié)果一致,進一步證實了下調(diào)URG11具有誘導骨肉瘤細胞凋亡的作用。
骨肉瘤具有較高的侵襲和轉(zhuǎn)移性[19];而EMT與侵襲和遷移相關(guān),且EMT的腫瘤細胞轉(zhuǎn)移能力更強[20]。E-cadherin和Vimentin是細胞EMT的標志[21-23]。骨肉瘤組織中E-cadherin呈低表達,而Vimentin高表達[24]。研究也顯示,沉默Vimentin能夠抑制肝癌細胞的遷移和侵襲[25]。本實驗結(jié)果顯示,下調(diào)URG11后的骨肉瘤細胞中E-cadherin水平升高,Vimentin水平降低,說明下調(diào)URG11可以抑制骨肉瘤細胞EMT。
此外,基質(zhì)金屬蛋白酶也與細胞轉(zhuǎn)移相關(guān),其可通過降解細胞外基質(zhì)促進細胞轉(zhuǎn)移[26]。MMP-9和MMP-2是基質(zhì)金屬蛋白酶的成員[27-28]。FOXF1-AS1通過MMP-2/-9途徑促進骨肉瘤細胞的遷移和侵襲[29];下調(diào)MMP-9表達可抑制人骨肉瘤細胞轉(zhuǎn)移[30]。本文的實驗結(jié)果顯示,下調(diào)URG11后的骨肉瘤細胞中MMP-2和MMP-9表達水平均下降,說明下調(diào)URG11可以抑制骨肉瘤細胞遷移和侵襲,URG11具有抗骨肉瘤細胞轉(zhuǎn)移潛能。
總之,本文結(jié)果證實了下調(diào)URG11具有抗骨肉瘤細胞增殖、侵襲、遷移、EMT和誘導凋亡的作用,URG11表達可能是靶向治療骨肉瘤的潛在靶點。本文結(jié)果為研究URG11在腫瘤中的作用提供了參考。本次實驗研究沒有在體內(nèi)和多株骨肉瘤細胞中進行驗證,后續(xù)會對上述部分內(nèi)容及其具體的調(diào)控網(wǎng)絡進行探索。
[參考文獻]
[1]孫光雨,李昊,裴艷濤. 靶向SOX4基因的慢病毒感染對骨肉瘤MG63細胞凋亡的影響[J].?鄭州大學學報(醫(yī)學版), 2018,53(6):64-68.
[2]LIU Ke, HUANG Jun, NI Jiangdong, et al. MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p[J].?Cell Cycle, 2017,16(6):578-587.
[3]SUDA T, TSUNODA T, DAIGO Y, et al. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy[J].?Cancer Science, 2007,98(11):1803-1808.
[4]DU Rui, XIA Lin, SUN Shiren, et al. URG11 promotes gastric cancer growth and invasion by activation of beta-catenin signalling pathway[J].?Journal of Cellular and Molecular Medicine, 2010,14(3):621-635.
[5]謝華紅,劉杰. URG11在肝癌組織表達增強并促進肝癌細胞生長[J].?細胞與分子免疫學雜志, 2015,31(11):1523-1527.
[6]謝偉東. 上調(diào)基因-11在骨肉瘤中的表達及其臨床意義[J].?實用中西醫(yī)結(jié)合臨床, 2017,17(1):126-128.
[7]姚楊,蘇杰,劉凱歌,等. 上調(diào)基因-11(URG11)生物信息學與功能分析[J].?生物技術(shù)通報, 2016,32(3):203-208.
[8]TONG Guangdong,?ZHANG Xi,?ZHOU Daqiao, et al. Efficacy of early treatment on 52 patients with preneoplastic hepatitis B virus-associated hepatocellular carcinoma by compound Phyllanthus Urinarial[J].?Chinese Journal of Integrative Medicine, 2014,20(4):263-271.
[9]潘斌,鄧志海,吳友科,等. 沉默URG11基因?qū)η傲邢侔㎜NCaP細胞增殖、遷移與侵襲的影響[J].?中國病理生理雜志, 2016,32(4):658-664.
[10]PENG Wei, ZHANG Jun, LIU Jie. URG11 predicts poor prognosis of pancreatic cancer by enhancing epithelial-mesenchymal transition-driven invasion[J].?Medical Oncology, 2014,31(7):1-7.
[11]FAN Rui, LI Xiaohua, DU Wenqi, et al. Adenoviral-mediated RNA interference targeting URG11 inhibits growth of human hepatocellular carcinoma[J].?International Journal of Cancer, 2011,128(12):2980-2993.
[12]LPEZ-GARCA C, SANSREGRET L, DOMINGO E, et al. BCL9L Dysfunction impairs caspase-2 expression permitting aneuploidy tolerance in colorectal cancer[J].?Cancer Cell, 2017,31(1):79-93.
[13]ZHANG Rui, XU Jian, ZHAO Jian, et al. Knockdown ofmiR-27a sensitizes colorectal cancer stem cells to TRAIL bypromoting the formation of Apaf-1-caspase-9 complex[J].?Oncotarget, 2017,8(28):45213-45223.
[14]PU X, STORR S J, ZHANG Y M, et al. Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival[J].?Apoptosis, 2017,22(3):357-368.
[15]ASSUMPO L D, GONALVES B V, AGUIRRE B L, et al. Immunoexpression of cleaved caspase-3 shows lower apoptotic area indices in lip carcinomas than in intraoral cancer[J].?Journal of Applied Oral Science: Revista FOB, 2016,24(4):359-365.
[16]KOYUNCU I, GONEL A, KOCYIGIT A, et al. Selective inhibition of carbonic anhydrase-Ⅸ by sulphonamide derivatives induces pH and reactive oxygen species-mediated apoptosis in cervical cancer HeLa cells[J].?Journal of Enzyme Inhibition & Medicinal Chemistry, 2018,33(1):1137-1149.
[17]梅紅軍,劉洋. 蟲草素對人骨肉瘤MG-63細胞凋亡的影響及其機制研究[J].?醫(yī)學研究雜志, 2018,47(12):81-84.
[18]朱韜,鄭有卯. 雷公藤紅素誘導人骨肉瘤細胞系HOS凋亡及機制研究[J].?浙江中西醫(yī)結(jié)合雜志, 2015,25(8):723-726.
[19]孫大菊,張玉成,王雅麗. Decorin對骨肉瘤MG63細胞侵襲和轉(zhuǎn)移的影響[J].?中國實驗診斷學, 2017,21(11):1987-1990.
[20]ZHANG M, WU W B, WANG Z W, et al. lncRNA NEAT1 is closely related with progression of breast cancer via promoting proliferation and EMT[J].?European Review for Medical and Pharmacological Sciences, 2017,21(5):1020-1026.
[21]CHEN Feifei, LIU Xin, CHENG Qian, et al. RUNX3 regulates renal cell carcinoma metastasis via targeting miR-6780a-5p/E-cadherin/EMT signaling axis[J].?Oncotarget, 2017,8(60):101042-101056.
[22]SATELLI A, BATTH I, BROWNLEE Z, et al. EMT circulating tumor cells detected by cell-surface vimentin are asso-
ciated with prostate cancer progression[J].?Oncotarget, 2017,8(30):49329-49337.
[23]SHAN Tao, CHEN Shuo, CHEN Xi, et al. Prometastatic mechanisms of CAF-mediated EMT regulation in pancreatic cancer cells[J].?International Journal of Oncology, 2017,50(1):121-128.
[24]馮曉雷,吳俊毅. 骨肉瘤組織中E-鈣黏蛋白波形蛋白和纖維連接蛋白的表達及臨床意義[J]. 中國腫瘤, 2015,22(11):1315-1317.
[25]柳嚴,張德林,王國良,等. shRNA介導的波形蛋白基因沉默對肝癌細胞遷移、侵襲能力的影響[J].?鄭州大學學報(醫(yī)學版), 2018,53(6):48-52.
[26]張先燎,施鑫. 基質(zhì)金屬蛋白酶及金屬蛋白酶組織抑制劑與骨肉瘤侵襲轉(zhuǎn)移的關(guān)系[J].?醫(yī)學研究生學報, 2009,22(9):996-1000.
[27]RAO Q, CHEN Y, YEH C R, et al. Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ER beta/CCL2/CCR2 EMT/MMP9 signals[J].?Oncotarget, 2016,7(7):7842-7855.
[28]LIU Yusi, SUN Xiaojiao, FENG Jinfa, et al. MT2-MMP induces proteolysis and leads to EMT in carcinomas[J].?Oncotarget, 2016,7(30):48193-48205.
[29]ZHU Kunpeng, ZHANG Chunlin, MA Xiaolong. Antisense lncRNA FOXF1-AS1 promotes migration and invasion of osteosarcoma cells through the FOXF1/MMP-2/-9 pathway[J].?International Journal of Biological Sciences, 2017,13(9):1180-1191.
[30]CHANG P Y, HSIEH M J, HSIEH Y S, et al. Tricetin inhi-
bits human osteosarcoma cells metastasis by transcriptionally repressing MMP-9 via p38 and Akt pathways[J].?Environmental Toxicology, 2017,32(8):2032-2040.